Top Growth Trends in the Mantle Cell Lymphoma Therapeutics Market: Key Insights and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the mantle cell lymphoma therapeutics market size evolved in recent years?
The market for therapeutics in mantle cell lymphoma has seen a robust expansion in the past few years. The market, which stood at $2.42 billion in 2024, is anticipated to rise to $2.62 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.2%. The past growth was fueled by advancements in research, successful clinical trials, enhancement in diagnostic tools, broader access to treatment, and cooperative research efforts.
What are the predictions for the mantle cell lymphoma therapeutics market size in the coming years?
The market size for therapeutics related to mantle cell lymphoma is projected to witness robust expansion in the ensuing years, reaching a valuation of “$3.56 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. The projected growth over this period can be credited to progress in targeted therapies, advances in immunotherapy, trends in personalized medicine, global market proliferation, and rising incidence rates. Major advancements that will shape the market during the forecast period include breakthroughs in immunotherapy, precision medicine and biomarker discovery, targeted therapies aimed at specific biological pathways, combined therapies, and the incorporation of artificial intelligence (AI).
Get your mantle cell lymphoma therapeutics market report here!
What key factors are fueling the growth of the mantle cell lymphoma therapeutics market?
An increase in the incidence of mantle cell lymphoma is anticipated to spur the growth of the mantle cell lymphoma therapeutics market. Mantle cell lymphoma (MCL) is a form of non-Hodgkin lymphoma (NHL), a cancer that affects the lymphatic system. Therapeutics for Mantle Cell Lymphoma aim to lower the disease’s incidence by effectively treating, managing the disease, enhancing patient outcomes, extending survival, and lessening disease burden. For example, in December 2022, data from the National Library of Medicine, a biomedical library run by the United States Federal Government, indicated that the yearly incidence of mantle cell lymphoma is one case per 200,000 people, accounting for 5% of all non-Hodgkins lymphomas. Hence, the increasing incidence of mantle cell lymphoma is fueling the expansion of the mantle cell lymphoma therapeutics market.
How is the global mantle cell lymphoma therapeutics market divided into key segments?
The mantle cell lymphoma therapeutics market covered in this report is segmented –
1) By Type: Combination Therapy, Monotherapy
2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors, Alkylating Agents, Deoxyribonucleic Acid Synthesis Inhibitors, Microtubule Inhibitors, Monoclonal Antibodies, Other Mechanisms
3) By Route of Administration: Oral, Parenteral
4) By Application: Hospital, Research Institute, Other Applications
Subsegments:
1) By Combination Therapy: Chemotherapy Combinations, Targeted Therapy Combinations, Immunotherapy Combinations
2) By Monotherapy: Single-Agent Chemotherapy, Targeted Therapy Monotherapy, Immunotherapy Monotherapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10813&type=smp
Who are the key firms paving the way for growth in the mantle cell lymphoma therapeutics market?
Major companies operating in the mantle cell lymphoma therapeutics market include AstraZeneca plc, Celgene Corporation, Johnson & Johnson Consumer Inc., Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Massive Bio Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astex Pharmaceuticals Inc., Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Exelixis Inc., Hutchison China MediTech Limited, Incyte Corporation, Ionis Pharmaceuticals Inc.
Which trends are expected to transform the mantle cell lymphoma therapeutics market?
The trend of developing drugs for targeted therapy is gaining momentum in the mantle cell lymphoma therapeutics market and is seen as a key trend. To maintain their market dominance, major firms specializing in mantle cell lymphoma therapeutics are focusing on the creation of new targeted therapy drugs. For example, UK-based pharmaceutical company AstraZeneca plc. received approval to market their drug, Calquence (acalabrutinib) in China for adult patients diagnosed with mantle cell lymphoma (MCL) from National Medical Products Administration (NMPA) in March 2023. Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, presents a fresh and effective treatment approach that aids the management of mantle cell lymphoma.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10813
What regions are contributing significantly to the growth of the mantle cell lymphoma therapeutics market?
North America was the largest region in the global mantle cell lymphoma therapeutics market in 2024. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Chemotherapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Testosterone Replacement Therapy Global Market Report 2024
Cellulose Acetate Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cellulose-acetate-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
